---
title: "Why Wall Street can't get enough of this dividend king"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293825844.md"
description: "AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend."
datetime: "2026-07-25T15:30:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293825844.md)
  - [en](https://longbridge.com/en/news/293825844.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293825844.md)
generator: "portal-rs"
---

# Why Wall Street can't get enough of this dividend king

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [This Dividend Stock Is Set for Growth and Its Yield Matches the 10-Year Treasury](https://longbridge.com/en/news/296944835.md)
- [Permian Basin Royalty Trust declares $0.0187 dividend](https://longbridge.com/en/news/296740052.md)
- [Mega IPOs Could be Coming: Here’s How They Might Impact Dividends](https://longbridge.com/en/news/296815476.md)
- [Dividend Hike and Higher Yield Might Change The Case For Investing In Tompkins Financial (TMP)](https://longbridge.com/en/news/296966974.md)
- [3 Closed-End Funds to Maximize Dividend Payments](https://longbridge.com/en/news/296706116.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**